UK Medtech Industry Points The Signpost At Better Adoption of Innovation
Often seen as complicated to access, beset with high entry barriers and with no guarantee of product adoption, the UK NHS is at once a lucrative and tricky market to succeed in for medtech innovators. A new MedTech Landscape Review, from the AHSN Network, has taken on the tasks of signposting and explaining the system, its adoption pathways and its various tools and programs, in an effort to point the way for manufacturers who want to access the NHS.
You may also be interested in...
A new remit for the NHS’ innovation vehicles, hopes for Integrated Care Systems and a new diagnostics trends report from Deloitte were on the agenda at a UK life sciences sector policy conference.
Changes are being made to the UK’s Accelerated Access Collaborative to help streamline access to ground-breaking medicines and diagnostic tools in areas like dementia, diabetes and cancer.
The new "NHS Long Term Plan" is an opportunity for an expansive vision in the UK, but it will fall short in its ambitious aims if it merely defaults to old, failed concepts of annualized, silo-nature NHS budgeting. These have proven to be a persistent and significant barrier to the introduction of innovation, says Peter Ellingworth, chief executive of the Association of British HealthTech Industries (ABHI).